angiotensin II receptor blockers (candesartan)
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2003 Sep 6;362(9386):777-81 Randomized Controlled Trial
IN heart failure, chronic, diastolic (preserved ejection fraction) The Use of
angiotensin II receptor blockers (candesartan)
As Treatment, Chronic
Is better Than
placebo
To reduce at 3 years admissions to hospital for heart failure (15,2% candesartan VS 18,4% placebo). Cardiovascular death did not differ. Primary composite outcome of both did neither differ
Lancet. 2003 Sep 6;362(9386):767-71 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers (candesartan), added to angiotensin converting enzyme inhibitors
As Treatment, Chronic
Is better Than
angiotensin converting enzyme (ACE) inhibitors alone
To reduce, at 3.5 years, cardiac events (cardiac death or hospital admission for heart failure): 38% with sartan added VS 42% with AECI alone
Lancet. 2003 Sep 6;362(9386):772-6 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers (candesartan), as sustitute of non tolered angiotensin converting enzyme inhibitors
As Treatment, Chronic
Is better Than
placebo
To reducing combined outcome cardio-vascular death or hospital admission for heart failure (33% in intv. / 40% in cont. in 34 months)